Middle East and Africa Anti diabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)and Geography -Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis2012-2016 and Forecast 2017-2023

Market Outline: Middle East and Africa Anti diabetic Biosimilars Market

Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

Market Dynamics: Middle East and Africa Anti diabetic Biosimilars Market

Drivers:

• Increase in the prevalence of diabetes
• Low cost of biosimilars compared with reference biologic molecules
• Expansion of business by the market players

Restraints:

• High cost and longer duration of R&D activities
• Stringent regulatory policies
• Complexity in development of biosimilars

Market Scope: Middle East and Africa Anti-diabetic Biosimilars Market

Middle East and Africa Anti-diabetic biosimilars market is segmented on the basis of drug class, disease type, distribution channel, and region

Based on the drug class, Middle East and Africa Anti-diabetic biosimilars market is segmented into the following:

• Insulin
• Biguanides
• Sulfonyl Ureas
• Thiazolidinediones
• Di Peptidyl Peptidase (DPP)-IV Inhibitors
• ?-glucosidase Inhibitos
• GLP-1 Agonists
• Others

Based on the disease type, Middle East and Africa Anti-diabetic biosimilars market is segmented into the following:

• Type-I Diabetes
• Type-II Diabetes

Based on the distribution channel, Middle East and Africa Anti-diabetic biosimilars market is segmented into the following:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the Country, Middle East and Africa Anti-diabetic biosimilars market is segmented into the following:

• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

Competition Assessment: Middle East and Africa Anti-diabetic Biosimilars Market

Some of the players in the Middle East and Africa Anti-diabetic biosimilars market include:

• Merck Sharp & Dohme Corporation (U.S.)
• Boehringer Ingelheim GmbH (Germany)
• Eli Lilly & Co. (U.S.)
• Sanofi-aventis U.S. LLC (U.S.)
• Samsung Bioepis (Samsung BioLogics) (South Korea)
• Mylan N.V. (U.S.)
• Wockhardt (India)

Key Features of the Report:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key marketdevelopments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

---

Location

GEOGRAPHY